Expects cash, cash equivalents and investments, and revenue it expects to generate from XPOVIO net product sales, as well as revenue generated from its license agreements, sufficient to fund planned operations into late 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KPTI:
- Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
- Karyopharm Regains Compliance, Secures Nasdaq Listing
- KPTI Earnings this Week: How Will it Perform?
- Karyopharm CFO Michael Mason sell 4,205 shares
- Biotech Alert: Searches spiking for these stocks today
